Clinical Trial Update: ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin [Phase 2]

View source ↗

Summary

A completed Phase 2 trial evaluated gefitinib (Iressa) in patients with recurrent or metastatic squamous cell carcinoma of the skin; results were posted in 2015…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Skin

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Skin Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-02-12